RedHawk (SNDD) 10-K 28 Oct 16 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2016	Sep. 15, 2016	Dec. 31, 2015
Document And Entity Information
Entity Registrant Name	RedHawk Holdings Corp.
Entity Central Index Key	1,353,406
Document Type	10-K
Trading Symbol	IDNG
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 1,805,583
Entity Common Stock, Shares Outstanding		357,072,547
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current Assets:
Cash and cash equivalents	$ 727,631	$ 900
Marketable securities, at market value	339,032
Receivables	472,584	610
Inventory	113,795	9,756
Prepaid expenses	21,295
Total Current Assets	1,674,337	11,266
Property and Improvements:
Land	110,000
Building and improvements	670,000
Total Property and Improvements, Gross	780,000
Less, accumulated depreciation	(18,479)
Total Property and Improvements	761,521
Other Assets:
Investment in real estate limited partnership	625,000
Equity investment in and advances to limited liability company	407,271
Intangible assets, net of accumulated amortization of $149,744 and $86,080, respectively	170,687	234,351
Total Other Assets	1,202,958	234,351
Total Assets	3,638,816	245,617
Current Liabilities:
Accounts payable and accrued liabilities	825,934	87,980
Current maturities of long-term debt	8,451
Line of credit	1,000,495
Due to related party		28,635
Loans payable		156,697
Insurance notes payable	14,178
Total Current Liabilities	1,849,058	273,312
Long-Term Debt:
Real estate note payable, net of current maturities	251,252
Convertible notes payable, net of $34,791 in deferred loan costs and unamortized beneficial conversion of $63,092	242,117
Total Long-Term Debt	493,369
Total Liabilities	2,342,427	273,312
Commitments and Contingencies
Stockholders' Equity (Deficit):
Common Stock, par value of $0.001 per share, 450,000,000 authorized shares and 375,094,082 issued and 357,072,547 outstanding at June 30, 2016 and 375,000,000 authorized shares and 360,094,082 issued and outstanding at June 30, 2015	375,094	360,094
Additional paid-in capital	1,192,283	927,826
Accumulated other comprehensive loss	(38,860)
Accumulated deficit	(2,646,026)	(1,315,615)
Total Stockholders' Equity (Deficit) Before Treasury Stock	1,372,491	(27,695)
Less, Treasury stock 18,021,535 shares, at cost	(76,102)
Total Stockholders' Equity (Deficit)	1,296,389	(27,695)
Total Liabilities and Stockholders' Equity	3,638,816	245,617
5% Series A Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred Stock, value	1,240,000
Total Stockholders' Equity (Deficit)	1,240,000
5% Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred Stock, value	1,250,000
Total Stockholders' Equity (Deficit)	$ 1,250,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Amortization of intangible assets	$ 149,744	$ 86,080
Deferred loan costs	34,791
Unamortized beneficial conversion	$ 63,092
Preferred Stock, stated value (in dollars per share)	$ 1,000	$ 1,000
Preferred Stock, authorized	5,000	5,000
Preferred Stock, issued	2,490	2,490
Preferred Stock, outstanding	2,490	2,490
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, authorized	450,000,000	450,000,000
Common Stock, issued	375,094,082	375,000,000
Common Stock, outstanding	357,072,547	360,094,082
Treasury stock, shares	18,021,535
5% Series A Convertible Preferred Stock [Member]
Preferred Stock, stated value (in dollars per share)	$ 1,000	$ 1,000
Preferred Stock, authorized	2,750	2,750
Preferred Stock, dividend rate (in percent)	5.00%	5.00%
Preferred Stock, issued	1,240	1,240
Preferred Stock, outstanding	1,240	1,240
5% Series B Convertible Preferred Stock [Member]
Preferred Stock, stated value (in dollars per share)	$ 1,000	$ 1,000
Preferred Stock, authorized	1,250	1,250
Preferred Stock, dividend rate (in percent)	5.00%	5.00%
Preferred Stock, issued	1,250	1,250
Preferred Stock, outstanding	1,250	1,250

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	5 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jan. 31, 2015
Income Statement [Abstract]
Revenue	$ 385	$ 29,450	$ 225
Costs and Expenses:
Operating expenses	151	17,911	108
Professional fees	68,794	607,138	51,515
Management fees		487,128
Sales and marketing	173	104,304	2,019
Depreciation		18,479
Amortization of intangibles	28,860	68,664	57,220
General and administrative	8,022	140,048	86,512
Total Costs and Expenses	106,000	1,443,672	197,374
Operating Loss	(105,615)	(1,414,222)	(197,149)
Other Income (Expense):
Expiration of indebtedness		156,697
Amortization of discount on convertible debentures		(3,908)	(74,166)
Amortization of deferred financing charges			(1,264)
Loss on foreign currency exchange		(55,038)
Gain on change in fair value of derivative liability			24,029
Gain on the sale of marketable securities		59,834
Dividend income		23,866
Interest expense		(35,189)	(519)
Other Income (Expense)		146,262	(51,920)
Net Loss from Continuing Operations	(105,615)	(1,267,960)	(249,069)
Discontinued Operations:
Loss from discontinued operations			(147,739)
Income on Discontinued Operations			(147,739)
Net Loss	(105,615)	(1,267,960)	(396,808)
Other comprehensive loss:
Unrecognized loss on marketable securities		(38,860)
Comprehensive Loss	(105,615)	(1,306,820)	(396,808)
Preferred Stock Dividends		(62,552)
Comprehensive Loss Available for Common Stockholders	$ (105,615)	$ (1,369,372)	$ (396,808)
Net Loss Per Share
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted Average Shares Outstanding
Basic (in shares)	360,094,082	359,815,765	314,534,724
Diluted (in shares)	360,094,082	359,815,765	314,534,724

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	5 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jan. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss from continuing operations	$ (105,615)	$ (1,267,960)	$ (249,069)
Adjustments to reconcile net loss to net cash used in continuing operations:
Amortization of intangibles	28,860	68,664	57,220
Amortization of discount on convertible debentures		3,908	74,166
Amortization of deferred financing charges			1,264
Depreciation		18,479
Contributed management services		20,000
Expiration of indebtedness		(156,697)
Gain on change in fair value of derivative liability			(24,029)
Changes in operating assets and liabilities:
Accounts receivable	(385)	(471,974)	(225)
Inventory	324	(104,039)	(10,080)
Prepaid expense and deposits		(21,295)	3,100
Accounts payable and accrued liabilities	44,893	737,954	35,179
Due to related party	28,635
Net Cash Used in Operating Activities	(3,288)	(1,172,960)	(112,474)
CASH FLOWS FROM INVESTING ACTIVITIES
Net proceeds from the sale of marketable securities		1,477,800
Proceeds from asset acquisition			60,000
Investment in foreign limited liability company		(147,170)
Acquisition of intangible assets		(5,000)
Net Cash Provided by Investing Activities		1,325,630	60,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock		50,000	49,900
Proceeds from related party line of credit		71,365	15,100
Proceeds from the issuance of the Series B Preferred Stock		256,765
Proceeds from issuance of convertible notes		340,000
Preferred stock dividends declared		(62,552)
Deferred loan costs		(34,791)
Proceeds from bank line of credit		20,495
Principal payments on related party line of credit			(15,100)
Net proceeds from insurance note payable		14,178
Principal payments on long-term debt		(5,297)
Treasury stock acquired		(76,102)
Net Cash Provided by Financing Activities		574,061	49,900
NET CASH PROVIDED BY DISCONTINUED OPERATIONS			(530)
Increase in cash	(3,288)	726,731	(3,104)
Cash, Beginning of Period	4,188	900	7,292
Cash, End of Period	900	727,631	4,188
Non-Cash Investing and Financing Activities:
Land and building acquired in exchange for Series A Preferred Stock and assumption of debt		780,000
Partnership investment acquired in exchange for Series A Preferred Stock		625,000
Assumption of debt for land and building acquired		265,000
Related party line of credit converted into Series A Preferred Stock		$ 100,000
Marketable securities acquired in exchange for Series B Preferred Stock and assumption of debt		1,855,692
Assumption of debt in exchange for marketable securities acquired		$ 980,000
Issuance of stock for intangible assets			$ 320,431
Shares issued for the conversion of debt and accrued interest			147,212
Equity investment acquired in exchange for common stock		$ 260,000
Preferred stock dividends declared but unpaid		61,208
Supplemental Disclosures:
Interest paid		35,189
Income tax paid

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	5% Series A Convertible Preferred Stock [Member]	5% Series B Convertible Preferred Stock [Member]	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	ACCUMULATED OTHER COMPREHENSIVE LOSS [Member]	ACCUMULATED DEFICIT [Member]	TREASURY STOCK [Member]	Total
BALANCE, AT BEGINNING at Jan. 31, 2014			$ 129,304	$ 541,497		$ (813,192)		$ (142,391)
BALANCE, AT BEGINNING (IN SHARES) at Jan. 31, 2014			129,304,155
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of debt			$ 63,712	123,076				186,788
Conversion of debt (in shares)			63,711,722
Shares issued for acquisition of intangible assets			$ 152,172	228,259				380,431
Shares issued for acquisition of intangible assets (in shares)			152,172,287
Issuance of shares for cash			$ 14,906	34,994				49,900
Issuance of shares for cash (in shares)			14,905,918
Acquisitions:
Net loss						(396,808)		(396,808)
BALANCE, AT END at Jan. 31, 2015			$ 360,094	927,826		(1,210,000)		77,920
BALANCE, AT END (IN SHARES) at Jan. 31, 2015			360,094,082
Acquisitions:
Net loss						(105,615)		(105,615)
BALANCE, AT END at Jun. 30, 2015			$ 360,094	927,826		(1,315,615)		(27,695)
BALANCE, AT END (IN SHARES) at Jun. 30, 2015			360,094,082
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributed management services				20,000				20,000
Sale of unregistered securities		$ 250,000	$ 5,000	45,000				300,000
Sale of unregistered securities (in shares)		250	5,000,000
Acquisitions:
Commercial real estate	$ 215,000							215,000
Commercial real estate (in shares)	215
Investment in real estate partnership	$ 625,000							625,000
Investment in real estate partnership (in shares)	625
Corporate office	$ 300,000							300,000
Corporate office (in shares)	300
Equity investment in limited liability corporation			$ 10,000	250,000				260,000
Equity investment in limited liability corporation (in shares)			10,000,000
Working capital contribution		$ 1,000,000		(117,543)				882,457
Working capital contribution (in shares)		1,000
Conversion of shareholder line of credit	$ 100,000							100,000
Conversion of shareholder line of credit (in shares)	100
Re-purchase of securities							$ (76,102)	(76,102)
Re-purchase of securities (in shares)							18,021,535
Fair value of beneficial conversion on convertible notes				67,000				67,000
Preferred stock dividends declared						(62,552)		(62,552)
Unrecognized loss on marketable securities					$ (38,860)			(38,860)
Net loss						(1,267,960)		(1,267,960)
BALANCE, AT END at Jun. 30, 2016	$ 1,240,000	$ 1,250,000	$ 375,094	$ 1,192,283	$ (38,860)	$ (2,646,026)	$ (76,102)	$ 1,296,389
BALANCE, AT END (IN SHARES) at Jun. 30, 2016	1,240	1,250	375,094,082				18,021,535

NATURE OF OPERATIONS AND CONTIN

NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS	12 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS	1. NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS RedHawk Holdings Corp. (formerly Independence Energy Corp.) was incorporated in the State of Nevada on November 30, 2005 under the name “Oliver Creek Resources Inc.” At inception, we were organized to acquire, explore and develop natural resource properties in the United States. Effective August 12, 2008, we changed our name from “Oliver Creek Resources Inc.” to “Independence Energy Corp.” and opened for trading with the Over-the Counter Bulletin Board under the symbol “IDNG.” Effective October 13, 2015, by vote of a majority of the Company’s stockholders, the Company’s name was changed from “Independence Energy Corp.” to “RedHawk Holdings Corp.” On March 31, 2014, the Company acquired the exclusive right to distribute certain medical devices and changed the focus of its operations to include medical device distribution. We have expanded our operations to include specialized financial services, pharmaceutical sales, commercial real estate leasing and investment, and a specialized security system. Currently, we are a diversified holding company which, through our subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the Disintegrator™ Insulin Needle Destruction Unit, the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Its real estate leasing revenues are generated from a commercial property under a long-term lease. Additionally, the Company’s real estate investment unit holds limited liability company interest in a commercial restoration project in Hawaii. The Company’s financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy Corp., LLC holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner. In June 2014, the Company decided to discontinue its oil and gas exploration and production operations. Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will be able to continue as a going concern without further financing. Currently, the Company must continue to realize its assets to discharge its liabilities in the normal course of business. The Company has generated minimal revenues to date and has never paid any dividends on its common stock and is unlikely to pay any common stock dividends or generate significant earnings in the immediate or foreseeable future. For the year ended June 30, 2016, the Company had $29,450 in revenue, and a net loss of $1,267,960, and cash of $1,172,960 used in operating activities. As of June 30, 2016, the Company had a working capital deficit of $174,721 and an accumulated deficit of $2,646,026. The continuation of the Company as a going concern is dependent upon the continued financial support from its stockholders, the ability to raise equity or debt financing, and the attainment of profitable operations from the Company’s businesses in order to discharge its obligations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements of the Company as of June 30, 2016 and 2015 and for the five month period ended June 30, 2015 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (which we refer to as “GAAP”) pursuant to the rules and regulations of the SEC. The Company’s fiscal year-end was January 31 but was been changed to June 30 by vote of a majority of the Company’s board of directors on June 15, 2015. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Certain prior year amounts are sometimes reclassified to be consistent with the current year financial statement presentation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost. Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of long-lived assets, asset retirement obligations, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Revenue Recognition We derive revenue from several types of activities – medical device sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Our real estate leasing revenues are from certain commercial properties under long-term lease. The financial service revenue is from brokerage services earned in connection with debt placement services. Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents. Marketable Securities We determine the appropriate classification of our marketable securities at the time of purchase and reassess the appropriateness of the classification at each reporting date. At June 30, 2016, all marketable securities held by the Company have been classified as available-for-sale and, as a result, are stated at fair value with unrealized gains and losses included as a component of accumulated other comprehensive income or loss. Realized gains and losses on the sale of marketable securities are determined on a specific identification basis. Interest and dividend income is recorded when it is earned and deemed realizable by the Company. At June 30, 2016, the fair value of the marketable securities on hand, which consisted entirely of widely recognized publicly-traded securities, was $339,032. Gross unrealized loss on the fair market value of the marketable securities was $38,860 as of June 30, 2016. As of June 30, 2016, we had trade date receivables of $302,288 recorded which was related to a sale of securities that had a trade date prior to June 30, 2016 and a settlement date after that date. Accounts Receivable Accounts receivables are amounts due from customers of our medical device division and our financial services division. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of June 30, 2016 and 2015. Inventory Inventory consist of purchased thermometers and advanced bleeding control, non-compression hemostasis held for resale and are stated at the lower of cost or net realizable value utilizing the first-in, first-out method. Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 years. Building improvements are depreciated over a useful life of 5 to 10 years. Oil and Gas Property Costs During the year ended January 31, 2015, the Company decided to discontinue its oil and gas business and the relevant assets have been impaired. In June 2015, the Company assigned its working interest in the Quinlan wells to the operator of those wells in exchange for the cancellation of all amounts due to the operator, including any future liabilities related to the Quinlan wells. Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes, Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share, Comprehensive Income (Loss) ASC 220, Comprehensive Income Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company has marketable securities with a fair market value of $339,032 at June 30, 2016, which are all publicly traded securities with quoted prices in active markets. The fair value is based on Level 1 assumptions. The Company’s financial instruments consist principally of cash, marketable securities, accounts payable and accrued liabilities, and amounts due to related parties. Pursuant to ASC 820 and ASC 825, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Recent Accounting Pronouncements Development Stage The Company has limited operations and is considered to be in the development stage. During the year ended January 31, 2015, the Company elected to early adopt Accounting Standards Update (which we refer to as “ASU”) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued new guidance intended to change the criteria for recognition of revenue. The new guidance establishes a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. In July 2015, the FASB permitted early adoption and deferred the effective date of this guidance one year; therefore, it will be effective for the Company in the first quarter of fiscal 2019 and may be implemented retrospectively to all years presented or in the period of adoption through a cumulative adjustment. We are currently evaluating what impact the adoption of this guidance would have on our financial position, results of operations, cash flows and disclosures. Going Concern In August 2014, the FASB issued guidance on disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management’s evaluation of whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This assessment must be made in connection with preparing financial statements for each annual and interim reporting period. Management’s evaluation should be based on the relevant conditions and events that are known and reasonably knowable at the date the financial statements are issued. If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern, but this doubt is alleviated by management’s plans, the entity should disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that alleviate that substantial doubt. If conditions or events raise substantial doubt and the substantial doubt is not alleviated, the entity must disclose this in the footnotes. The entity must also disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that are intended to alleviate that substantial doubt. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. We do not expect that adoption will have a material impact on our financial position, results of operations, cash flows or disclosures. Debt Issuance Costs In April 2015, the FASB issued new guidance which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. Therefore, the amortization of such costs will continue to be calculated using the interest method and be reported as interest expense. The new guidance does not specifically address, and therefore does not affect, the balance sheet presentation of debt issuance costs for revolving debt arrangements. This new guidance is effective for the Company in the first quarter of fiscal 2017, and will be applied on a retrospective basis. Early adoption is permitted for financial statements that have not been previously issued. To date, our debt issuance cost of $34,791 as of June 30, 2016 has not been significant. As the Company continues to raise capital to execute its growth strategy, the use of debt in the future may have additional issuance costs to be accounted for under this guidance. Leases In February 2016, the FASB issued ASU 2016-02, Leases

FIXED ASSETS

FIXED ASSETS	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
FIXED ASSETS	3. FIXED ASSETS Properties and Improvements On November 12, 2015, we acquired certain commercial rental property, consisting of $75,000 of land and $405,000 of buildings and improvements, from a related party that is an entity controlled by a stockholder and officer of the Company, On December 31, 2015, we acquired certain commercial real estate from a related party, that is an entity controlled by a shareholder and officer of the Company, to be used as our corporate office, for $300,000 consisting of $35,000 of land and $265,000 of buildings and improvements. The purchase price was paid by the Company with the issuance of 300 shares of the Company’s Series A Preferred Stock. The purchase price of the property was determined by independent third-party appraisal. Oil and Gas Properties Effective June 1, 2015, we assigned 100% of our interest in the Quinlan wells to the operator of those wells in exchange for the cancellation of all current and future liabilities on the Quinlan wells.

OTHER ASSETS

OTHER ASSETS	12 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER ASSETS	4. OTHER ASSETS Tower Hotel Fund 2013, LLC On December 31, 2015, RedHawk Land & Hospitality, LLC acquired from Beechwood Properties, LLC 280,000 Class A Units (approximately a 2.0% membership interest) of fully paid, non-assessable units of limited liability company interest in Tower Hotel Fund 2013, LLC, a real estate development limited liability company formed in the state of Hawaii for acquisition, restoration and development of the Naniloa Hilo Resort in Hilo, Hawaii. The $625,000 purchase price was paid by the issuance of 625 shares of the Company’s Series A Preferred Stock. The purchase price was determined by an independent third-party valuation. Beechwood Properties, LLC is a real estate limited liability company owned and controlled by G. Darcy Klug, a stockholder and Chief Financial Officer and Chairman of the board of directors of the Company. Intangible Assets On March 31, 2014, the Company entered into an asset purchase agreement (which we refer to as the “Agreement”) with American Medical Distributors, LLC (which we refer to as “AMD”) pursuant to which the Company acquired a five-year license commencing on November 27, 2013 for the exclusive territorial distribution rights to the Thermofinder non-contact thermometer from AMD in exchange for the issuance of 152,172,287 shares of the Company’s common stock with a fair value of $320,431 based on the fair value of such shares on the date of issuance. As a part of this asset acquisition and share issuance, the Company also received a payment of $60,000. The intangible asset is being amortized over the remaining life of the license agreement. Amortization expense is expected to be approximately $69,000 per year for years 2017 and 2018 and approximately $33,000 in year 2019. On December 31, 2015, we acquired certain tangible and intangible high-quality medical device assets, including the Disintegrator™ Insulin Needle Destruction Unit (which we refer to as “NDD”) and the Carotid Artery Non-Contact Thermometer. The purchase price was paid by the issuance of 60,000,000 restricted shares of our common stock, which are subject to vesting based upon the completion by the seller of certain performance milestones including, but not limited to, successful completion of NDD upgrades, submission for worldwide patents for the NDD, completion of the first NDD production model, approval by the Company of the initial NDD production run, attaining certain NDD unit sales and profitability milestones, and receipt of final worldwide patents for the NDD. At June 30, 2016, none of the restricted shares had vested. On March 23, 2016, RedHawk Pharma UK Ltd acquired a 25% equity interest in EcoGen Europe Ltd (which we refer to as “EcoGen”) from Scarlett Pharma Ltd (which we refer to as “Scarlett”). The Company has agreed to issue to Scartlett up to 100 million restricted shares of common stock of the Company. Under the terms of the purchase agreement, 10 million shares were issued to Scarlett at closing with an additional 90 million shares (which we refer to as the “Earnout Shares”) to be issued and vested pro rata as EcoGen reports audited EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization). The issuance and vesting of the Earnout Shares will occur annually based upon audited results of EcoGen and will conclude with the earlier of EcoGen attaining cumulative EBITDA of $100 million or seven years from the closing date. Additionally, during the seven-year period commencing on the closing date, the Company has the right, but not the obligation, to increase its ownership position in EcoGen up to a maximum of 49% of the entire capital of EcoGen. Should the Company exercise its option to increase its ownership position, the Company will issue to Scarlett, pro rata, up to an additional 100 million restricted shares of the common stock of the Company. Concurrent with the execution of the purchase agreement, the Company entered into a consultancy agreement with Scarlett for the marketing and distribution in the United Kingdom and, where available, other European and Middle East countries, certain medical device products offered by RedHawk Medical Products UK Ltd.

LOAN AND INSURANCE NOTE PAYABLE

LOAN AND INSURANCE NOTE PAYABLE	12 Months Ended
	Jun. 30, 2016
Loans Payable [Abstract]
LOAN AND INSURANCE NOTE PAYABLE	5. LOAN AND INSURANCE NOTE PAYABLE We finance a portion of our insurance premiums. At June 30, 2016, the outstanding balance due on our premium finance agreement was $14,178. In December 2011, the Company received a loan in the amount of $156,697 from an unrelated third party. The loan was non-interest bearing, unsecured and due on demand. On December 11, 2015, the time frame to collect the loan by the third party had expired. Therefore, the loan was written off and recorded within other income/expense as expiration of indebtedness.

DUE TO RELATED PARTY

DUE TO RELATED PARTY	12 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
DUE TO RELATED PARTY	6. DUE TO RELATED PARTY Effective November 12, 2015, the Company entered into a $100,000 Commercial Note Line of Credit (which we refer to as the “Line of Credit”) with a stockholder and officer of the Company to evidence prior indebtedness and provide for future borrowings. The advances are used to fund our operations. The Line of Credit accrues interest at 5% per annum and matures on October 31, 2016. At maturity, or in connection with a pre-payment, subject to the conditions set forth in the Line of Credit, the stockholder has the right to convert the amount outstanding (or the amount of the prepayment) into the Company’s Series A Preferred Stock at the par value of $1,000 per share. At December 31, 2015, the principal balance plus accrued interest totaled $100,000. At that date, the stockholder elected to convert the outstanding principal and interest balance into 100 shares of our Series A Preferred Stock. At June 30, 2016, there is no outstanding balance on the Line of Credit.

LONG-TERM DEBT, DEBENTURES AND

LONG-TERM DEBT, DEBENTURES AND LINE OF CREDIT	12 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
LONG-TERM DEBT, DEBENTURES AND LINE OF CREDIT	7. LONG-TERM DEBT, DEBENTURES AND LINE OF CREDIT On November 12 The Note is dated November 13, 2015 and has a principal amount of $265,000. Monthly payments under the Note are $1,962 including interest accruing at a rate of 5.95% per annum. The Note matures in June 2021 and is secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company. We have authorized the issuance of up to $1 million in principal amount of convertible promissory notes (which we refer to as the “Convertible Notes”). The Convertible Notes are secured by certain Company real estate holdings and real estate holdings of a stockholder. The Convertible Notes mature on the fifth anniversary of the date of issuance and are convertible into shares of our common stock at a price of $0.015 per share. Interest accrues at a rate of 5% per annum and is payable semi-annually. Beginning 180 days after issuance of the Convertible Notes, the Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Convertible Notes. The Company may only issue the notice of its intent to redeem the Convertible Notes if the trading average of the Company’s common stock equals or exceeds 300% of the conversion price during each of the five business days immediately preceding the date of the notice of intent to redeem. The holder of the Convertible Notes has the right to convert all or any portion of the Convertible Notes at the conversion price at any time prior to redemption. At June 30, 2016, there were $340,000 ($242,117 net of deferred financing costs and beneficial conversion option) of Convertible Notes outstanding which are convertible into our common stock at a conversion rate of $0.015 per share or 23,002,083 shares. Subsequent to year end, we completed the funding of an additional $210,000 in Convertible Notes. Our line of credit with a bank totals $1,000,000 of which the entire amount was outstanding as of June 30, 2016. The line of credit is due upon demand and is secured by marketable securities, a corporate guarantee and the guarantee of a stockholder who is also an officer of the Company. Interest accrues at the rate of one-month LIBOR plus 2.75% and is paid monthly. The interest rate at June 30, 2016 was 3.47%.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Jun. 30, 2016
Stockholders' Equity (Deficit):
STOCKHOLDERS' EQUITY	8. STOCKHOLDERS’ EQUITY Effective on October 13, 2015, we amended and restated our articles of incorporation as previously adopted by a majority vote of our stockholders. The amended and restated articles of incorporation, among other things, changed our name to RedHawk Holdings Corp., authorized 5,000 shares of Preferred Stock, and increased the number of authorized shares of common stock from 375,000,000 to 450,000,000. Common Stock On October 15, 2015, we entered into a securities purchase agreement with an accredited investor for the sale of 5,000,000 shares of our common stock in exchange for $50,000. On February 9, 2016, we entered into a settlement agreement with a former officer and director in partial settlement of certain litigation. At the time of the settlement, the officer owned 18,021,535 shares of our common stock. In exchange for a payment of $42,500 and other consideration provided in the settlement, the Company purchased the shares owned by the former officer and returned those shares into the Company treasury. The Company incurred transaction costs of $33,602 in completing this equity transaction. On March 23, 2016, we issued 10,000,000 shares of our common stock, having a fair market value of $260,000, in connection with entering into a purchase agreement with Scatlett to acquire a 25% ownership interest in EcoGen (See Note 4). Preferred Stock Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective November 12, 2015, 2,750 shares of our authorized Preferred Stock have been designated as Series A 5% Convertible Preferred Stock, with a $1,000 stated value (which we refer to as “Series A Preferred Stock”). The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted. After nine months from issuance, each share of Series A Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.015, as adjusted for stock splits and dividends. On November 12, 2015, we issued 215 shares of our Series A Preferred Stock in connection with the acquisition of certain commercial real estate from a related party, which is an entity controlled by a stockholder and officer of the Company. On December 31, 2015, in exchange for 300 shares of our Series A Preferred Stock, we acquired from a related party, which is an entity controlled by a stockholder and officer of the Company, certain real estate to be used as our corporate offices (see Note 3). On December 31, 2015, we issued 625 shares of Series A Preferred Stock to acquire certain limited liability company membership interest in a real estate development located in Hawaii (See Note 4). On December 31, 2015, a stockholder and officer of the Company converted $100,000 of the outstanding principal and interest balance due to the stockholder in exchange for 100 shares of the Company’s Series A Preferred Stock (see Note 6). Pursuant to a certificate of designation filed with the Secretary of State of the State of Nevada, effective February 16, 2016, 1,250 shares of our authorized Preferred Stock have been designated as Series B 5% Convertible Preferred Stock, with a $1,000 stated value (which we refer to as “Series B Preferred Stock”). The holders of the Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series B Preferred Stock (which we refer to as “PIK”). Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted. After nine months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends. On December 30, 2015, we received, from a stockholder and officer of the Company, $1,862,458 of cash and marketable securities, net of a $980,000 line of credit balance, in exchange for 1,000 shares of our Series B Preferred Stock. On February 1, 2016, we received from an officer of the Company, $250,000 of cash in exchange for 250 shares of our Series B Preferred Stock. Warrants During November 2014, we completed a private equity sale of 14,905,918 shares of common stock generating proceeds of $49,900. As a component of this private equity sale, 7,7452,959 warrants to acquire common stock of the Company were also issued with an exercise price of $0.005 per share. During the year ended June 30, 2016, no warrants were exercised and 7,452,959 warrants remain outstanding. The warrants expire upon the close of business on November 7, 2016.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	12 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	9. DISCONTINUED OPERATIONS On June 23, 2014, the Company impaired its remaining oil and natural gas properties and changed its focus to medical device distribution and other businesses. The Company’s oil and gas properties were fully impaired in the year ended January 31, 2015 and the Company assigned its working interest in the oil and gas properties to the operator of those wells in exchange for the cancellation of all amounts due to the operator, including any future liabilities. As a result of the Company’s impairment of its oil and gas properties and change in direction for the Company’s business, all expenses related to the oil and natural gas operations have been classified as discontinued operations. The results of discontinued operations are summarized as follows: Twelve Months Ended Five Months June 30, 2016 January 31, 2015 June 30, 2015 Operating Loss $ - $ 147,739 $ - Net Loss from Discontinued Operations $ - $ 147,739 $ -

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES As of June 30, 2016 and 2015, the Company had approximately $2,400,000 and $1,100,000, respectively, of net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2026 and run through 2036. The related deferred income tax asset of these net operating losses is estimated to be $800,000 and $400,000 as of June 30, 2016 and 2015, respectively, based on statutory federal income tax rates in effect. However, there is no net tax asset recorded as a 100% valuation allowance has been established for the tax benefit generated. At June 30, 2016, the Company had no uncertain tax positions. The Company accounts for interest and penalties relating to uncertain tax provisions in the current period statement of income, as necessary. The Company has never filed a tax return. In order to utilize the available net operating loss carryforwards, the Company will need to prepare and file all tax returns since its inception. The Company’s tax years from inception are subject to examination. Due to our history of operating losses and the uncertainty surrounding the realization of the deferred tax assets in future years, our management has determined that it is more likely than not that the deferred tax assets will not be realized in future periods. Accordingly, the Company has recorded a valuation allowance against its net deferred tax assets.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
SEGMENT INFORMATION	11. SEGMENT INFORMATION SFAS No. 131, “Disclosures About Segments of an Enterprise and Related Information,” MEDICAL LAND & DEVICE & OTHER HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 24,700 $ - $ 4,750 $ - $ 29,450 Operating income (loss) $ (5,364 ) $ (521,025 ) $ (22,881 ) $ (864,952 ) $ (1,414,222 ) Interest expense $ 9,843 $ - $ - $ 25,346 $ 35,189 Depreciation and amortization $ 18,479 $ 68,664 $ - $ - $ 87,143 Identifiable assets $ 1,396,780 $ 917,902 $ 5,529 $ 1,318,605 $ 3,638,816

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company evaluates subsequent events through the time of our filing on the date we issue our financial statements, which was on October __, 2016. The following are matters which occurred subsequent to June 30, 2016. Subsequent to June 30, 2016, the Company issued an additional $210,000 of Convertible Notes to be used for acquisition investment and working capital. On September 26, 2016, the Company announced it had agreed to acquire up to a 25% interest in Marlin USA Energy Partners, LLC, the minority owner of Tigress Energy Partners, LLC. As of the date of this report, the Company has made a $70,000 cash investment related to this agreement. On October 25, 2016, the Company announced that it had received pre-market clearance from the U. S. Food and Drug Administration for the sale of its Sharps and Needle Destruction Device in the United States.

SUMMARY OF SIGNIFICANT ACCOUN19

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of the Company as of June 30, 2016 and 2015 and for the five month period ended June 30, 2015 included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (which we refer to as “GAAP”) pursuant to the rules and regulations of the SEC. The Company’s fiscal year-end was January 31 but was been changed to June 30 by vote of a majority of the Company’s board of directors on June 15, 2015.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries in which we have a greater than 50% ownership. All material intercompany accounts have been eliminated upon consolidation. Certain prior year amounts are sometimes reclassified to be consistent with the current year financial statement presentation. Equity investments, which we have an ownership greater than 20% but less than 50% through which we exercise significant influence over but do not control the investee and we are not the primary beneficiary of the investee’s activities, are accounted for using the equity method of accounting. Equity investments, which we have an ownership less than 20%, are recorded at cost.
Use of Estimates	Use of Estimates The financial statements and related notes are prepared in conformity with GAAP which requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation and impairment of long-lived assets, asset retirement obligations, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Revenue Recognition	Revenue Recognition We derive revenue from several types of activities – medical device sales, commercial real estate leasing and financial services. Our medical device sales include the marketing and distribution of certain professional and consumer grade digital non-contact thermometers, needle destruction unit and advanced bleeding control, non-compression hemostasis. Our real estate leasing revenues are from certain commercial properties under long-term lease. The financial service revenue is from brokerage services earned in connection with debt placement services.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider highly liquid investments with an original maturity of 90 days or less to be cash equivalents.
Marketable Securities	Marketable Securities We determine the appropriate classification of our marketable securities at the time of purchase and reassess the appropriateness of the classification at each reporting date. At June 30, 2016, all marketable securities held by the Company have been classified as available-for-sale and, as a result, are stated at fair value with unrealized gains and losses included as a component of accumulated other comprehensive income or loss. Realized gains and losses on the sale of marketable securities are determined on a specific identification basis. Interest and dividend income is recorded when it is earned and deemed realizable by the Company. At June 30, 2016, the fair value of the marketable securities on hand, which consisted entirely of widely recognized publicly-traded securities, was $339,032. Gross unrealized loss on the fair market value of the marketable securities was $38,860 as of June 30, 2016. As of June 30, 2016, we had trade date receivables of $302,288 recorded which was related to a sale of securities that had a trade date prior to June 30, 2016 and a settlement date after that date.
Accounts Receivable	Accounts Receivable Accounts receivables are amounts due from customers of our medical device division and our financial services division. The amount is reported at the billed amount, net of any expected allowance for bad debts. There was no allowance for doubtful accounts as of June 30, 2016 and 2015.
Inventory	Inventory Inventory consist of purchased thermometers and advanced bleeding control, non-compression hemostasis held for resale and are stated at the lower of cost or net realizable value utilizing the first-in, first-out method.
Property and Improvements	Property and Improvements Property and improvements are stated at cost. We provide for depreciation expense on a straight line basis over each asset’s useful life depreciated to their estimated salvage value. Buildings are depreciated over a useful life of 20 years. Building improvements are depreciated over a useful life of 5 to 10 years.
Oil and Gas Property Costs	Oil and Gas Property Costs During the year ended January 31, 2015, the Company decided to discontinue its oil and gas business and the relevant assets have been impaired. In June 2015, the Company assigned its working interest in the Quinlan wells to the operator of those wells in exchange for the cancellation of all amounts due to the operator, including any future liabilities related to the Quinlan wells.]
Income Taxes	Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted Accounting Standard Codification (which we refer to as “ASC”) 740, Income Taxes,
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, Earnings Per Share,
Comprehensive Income (Loss)	Comprehensive Income (Loss) ASC 220, Comprehensive Income
Financial Instruments	Financial Instruments Pursuant to ASC 820, Fair Value Measurements and Disclosures Level 1. Level 2. Level 3. The Company has marketable securities with a fair market value of $339,032 at June 30, 2016, which are all publicly traded securities with quoted prices in active markets. The fair value is based on Level 1 assumptions. The Company’s financial instruments consist principally of cash, marketable securities, accounts payable and accrued liabilities, and amounts due to related parties. Pursuant to ASC 820 and ASC 825, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Development Stage The Company has limited operations and is considered to be in the development stage. During the year ended January 31, 2015, the Company elected to early adopt Accounting Standards Update (which we refer to as “ASU”) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements Revenue Recognition In May 2014, the Financial Accounting Standards Board (which we refer to as the “FASB”) issued new guidance intended to change the criteria for recognition of revenue. The new guidance establishes a single revenue recognition model for all contracts with customers, eliminates industry specific requirements and expands disclosure requirements. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following five steps: (1) identify contracts with customers, (2) identify the performance obligations in the contracts, (3) determine the transaction price, (4) allocate the transaction price to the performance obligation in the contract, and (5) recognize revenue as the entity satisfies performance obligations. In July 2015, the FASB permitted early adoption and deferred the effective date of this guidance one year; therefore, it will be effective for the Company in the first quarter of fiscal 2019 and may be implemented retrospectively to all years presented or in the period of adoption through a cumulative adjustment. We are currently evaluating what impact the adoption of this guidance would have on our financial position, results of operations, cash flows and disclosures. Going Concern In August 2014, the FASB issued guidance on disclosures of uncertainties about an entity’s ability to continue as a going concern. The guidance requires management’s evaluation of whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This assessment must be made in connection with preparing financial statements for each annual and interim reporting period. Management’s evaluation should be based on the relevant conditions and events that are known and reasonably knowable at the date the financial statements are issued. If conditions or events raise substantial doubt about the entity’s ability to continue as a going concern, but this doubt is alleviated by management’s plans, the entity should disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that alleviate that substantial doubt. If conditions or events raise substantial doubt and the substantial doubt is not alleviated, the entity must disclose this in the footnotes. The entity must also disclose information that enables the reader to understand what the conditions or events are, management’s evaluation of those conditions or events and management’s plans that are intended to alleviate that substantial doubt. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. We do not expect that adoption will have a material impact on our financial position, results of operations, cash flows or disclosures.
Debt Issuance Costs	Debt Issuance Costs In April 2015, the FASB issued new guidance which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The new guidance does not affect the recognition and measurement of debt issuance costs. Therefore, the amortization of such costs will continue to be calculated using the interest method and be reported as interest expense. The new guidance does not specifically address, and therefore does not affect, the balance sheet presentation of debt issuance costs for revolving debt arrangements. This new guidance is effective for the Company in the first quarter of fiscal 2017, and will be applied on a retrospective basis. Early adoption is permitted for financial statements that have not been previously issued. To date, our debt issuance cost of $34,791 as of June 30, 2016 has not been significant. As the Company continues to raise capital to execute its growth strategy, the use of debt in the future may have additional issuance costs to be accounted for under this guidance.
Leases	Leases In February 2016, the FASB issued ASU 2016-02, Leases

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	The results of discontinued operations are summarized as follows: Twelve Months Ended Five Months June 30, 2016 January 31, 2015 June 30, 2015 Operating Loss $ - $ 147,739 $ - Net Loss from Discontinued Operations $ - $ 147,739 $ -

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Schedule of corporate operating activities	The following table reflects our segments as of June 30, 2016 and for the year then ended. For periods prior to the year ended June 30, 2016, we did not have separately identifiable segments. MEDICAL LAND & DEVICE & OTHER HOSPITALITY PHARMA SERVICES CORPORATE TOTAL Operating revenues $ 24,700 $ - $ 4,750 $ - $ 29,450 Operating income (loss) $ (5,364 ) $ (521,025 ) $ (22,881 ) $ (864,952 ) $ (1,414,222 ) Interest expense $ 9,843 $ - $ - $ 25,346 $ 35,189 Depreciation and amortization $ 18,479 $ 68,664 $ - $ - $ 87,143 Identifiable assets $ 1,396,780 $ 917,902 $ 5,529 $ 1,318,605 $ 3,638,816

NATURE OF OPERATIONS AND CONT22

NATURE OF OPERATIONS AND CONTINUANCE OF BUSINESS (Details Narrative) - USD ($)	5 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jan. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue	$ 385	$ 29,450	$ 225
Net loss	(105,615)	(1,267,960)	(249,069)
Net cash used in operating activities	(3,288)	(1,172,960)	$ (112,474)
Working capital deficit		174,721
Accumulated deficit	$ (1,315,615)	$ (2,646,026)

SUMMARY OF SIGNIFICANT ACCOUN23

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	5 Months Ended	12 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jan. 31, 2015
Marketable securitie, amortized cost basis			$ 339,032
Gross unrealized losses			(38,860)
Trade date receivables			$ 302,288
Potentially anti - dilutive shares excluded from computation of loss per share			23,002,083
Incremental common shares issuable upon conversion of debt Securities	7,452,959		7,452,959	7,452,959
Marketable securities, at market value			$ 339,032
Debt issuance cost			$ 34,791
5% Series A Convertible Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock			82,666,666
5% Series B Convertible Preferred Stock [Member]
Incremental common shares issuable upon conversion of preferred stock			125,000,000
Building [Member]
Useful life			20 years
Minimum [Member] | Building Improvements [Member]
Useful life			5 years
Maximum [Member] | Building Improvements [Member]
Useful life			10 years
Subsidiaries [Member]
Percentage of ownership			50.00%
Subsidiaries [Member] | Minimum [Member]
Equity method ownership percentage			20.00%
Subsidiaries [Member] | Maximum [Member]
Equity method ownership percentage			50.00%

FIXED ASSETS (Details Narrative

FIXED ASSETS (Details Narrative) - USD ($)	Dec. 31, 2015	Nov. 12, 2015	Jun. 01, 2015
Related Party [Member]
Payment to acquired real estate from a related party	$ 300,000	$ 480,000
Purchase price from acquisition		$ 265,000
Related Party [Member] | 5% Series A Convertible Preferred Stock [Member]
Number of shares issuance (in shares)	300	215
Related Party [Member] | Building Improvements [Member]
Payment to acquired real estate from a related party	$ 265,000	$ 405,000
Related Party [Member] | Land [Member]
Payment to acquired real estate from a related party	$ 35,000	75,000
Unrelated Party [Member]
Base rent		$ 3,250
Pottawatomie County Oklahoma [Member]
Working interest percentage acquired in oil and gas property			100.00%

OTHER ASSETS (Details Narrative

OTHER ASSETS (Details Narrative) - USD ($)	Mar. 23, 2016	Dec. 31, 2015	Mar. 31, 2014	Jun. 30, 2016
Asset Purchase Agreement [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Description of acquired assets		Tangible and intangible high-quality medical device assets, including the Disintegrator™ Insulin Needle Destruction Unit (“NDD”).
Description of contingent consideration arrangements		Vesting based upon the completion by the seller of certain performance milestones including, but not limited to, successful completion of NDD upgrades, submission for worldwide patents for the NDD.
Asset Purchase Agreement [Member] | American Medical Distributors, LLC [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Stock issued during period for acquisition of license			152,172,287
Value of stock issued during period for acquisition of license			$ 320,431
Proceeds from acquisition transaction			$ 60,000
Amortization expense, year ended 2017				$ 69,000
Amortization expense, year ended 2018				69,000
Amortization expense, year ended 2019				$ 33,000
Restricted Common Shares [Member] | Asset Purchase Agreement [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Number of shares issued upon acquisition		60,000,000
EcoGen Europe Limited ("EcoGen") [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percentage of ownership	25.00%
Period Of issuance and vesting of the earnout shares EBITDA	7 years
EcoGen Europe Limited ("EcoGen") [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percentage of ownership				49.00%
EcoGen Europe Limited ("EcoGen") [Member] | Restricted Stock [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Number of shares issued	100,000,000
Scarlett Pharma Ltd ("Scarlett") [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Number of shares issued	10,000,000
Additional number of shares issued	90,000,000			100,000,000
G. Darcy Klug (Beechwood Properties, LLC) [Member] | Tower Hotel Fund 2013 LLC [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Number of untits acquired		280,000
Percentage of membership interest acquired		2.00%
G. Darcy Klug (Beechwood Properties, LLC) [Member] | Tower Hotel Fund 2013 LLC [Member] | 5% Series A Convertible Preferred Stock [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Purchase price from acquisition		$ 625,000
Number of shares issued upon acquisition		625

LOAN AND INSURANCE NOTE PAYAB26

LOAN AND INSURANCE NOTE PAYABLE (Details Narrative) - USD ($)	1 Months Ended
	Dec. 31, 2011	Jun. 30, 2016	Jun. 30, 2015
Insurance notes payable		$ 14,178
Loans payable			$ 156,697
Unsecured Non-Interest Bearing Loan Payable [Member] | Unrelated Third Party [Member]
Loans payable	$ 156,697
Description of maturity	Due on demand

DUE TO RELATED PARTY (Details N

DUE TO RELATED PARTY (Details Narrative) - USD ($)	Dec. 31, 2015	Nov. 12, 2015	Jun. 30, 2016	Jun. 30, 2015
Preferred stock, par value (in dollars per share)			$ 1,000	$ 1,000
Related Party [Member] | Loan Agreement With Bank [Member]
Debt conversion amount	$ 100,000
5% Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)		$ 1,000	$ 1,000	$ 1,000
5% Series A Convertible Preferred Stock [Member] | Related Party [Member]
Number of shares issued upon conversion	100
Line of Credit [Member]
Maximum borrowing capacity		$ 100,000
Line of Credit [Member] | 5% Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)		$ 1,000
Expiration date		Oct. 31, 2016
Interest rate		5.00%
Convertible debt, terms of conversion feature		The stockholder elected to convert the outstanding principal and interest balance into 100 shares of our Series A Preferred Stock.

LONG-TERM DEBT, DEBENTURES AN28

LONG-TERM DEBT, DEBENTURES AND LINE OF CREDIT (Details Narrative) - USD ($)	Dec. 31, 2015	Nov. 13, 2015	Nov. 12, 2015	Jun. 30, 2016	Jun. 30, 2015
Convertible debentures outstanding				$ 242,117
Bank [Member] | 3.18% Line of Credit Due Upon Demand [Member]
Interest rate				3.47%
Line of credit maximum borrowing capacity				$ 1,000,000
Description of line of credit collateral				Secured by marketable securities, a corporate guarantee and the guarantee of a stockholder who is also an officer of the Company.
Line of credit, frequency of interest payment				Monthly
Description of line of credit interest rate				One-month LIBOR plus 2.75%
Loan Agreement With Bank [Member]
Debt instrument, face amount		$ 265,000
Debt instrument, issuance date		Nov. 13, 2015
Interest rate		5.95%
Description of maturity		June 2,021
Description of collateral		The Note matures in June 2021 and is secured by the commercial real estate, guarantees by the Company and its real estate subsidiary and the personal guarantee of a stockholder who is also an officer of the Company.
Debt instrument, monthly payment		$ 1,962
Line of credit, frequency of interest payment		Monthly
5% Secured Convertible Notes Payable [Member]
Debt instrument, face amount				$ 1,000,000
Description of maturity				Mature on the fifth anniversary of the date of issuance.
Description of collateral				Secured by certain Company real estate holdings and real estate holdings of a stockholder.
Conversion price (in dollars per share)				$ 0.015
Debt instrument, frequency of interest payment				Semi-annually
Description of call feature				Beginning 180 days after issuance of the Convertible Notes, the Company has the option to issue a notice of its intent to redeem, for cash, an amount equal to the sum of (a) 120% of the then outstanding principal balance, (b) accrued but unpaid interest and (c) all liquidated damages and other amounts due in respect of the Convertible Notes.
Debt instrument, convertible threshold percentage of stock price trigger				300.00%
Debt instrument, convertible threshold trading days				5 days
Convertible debentures outstanding				$ 340,000
Deferred financing costs and beneficial conversion				$ 242,117
Number of converted shares				23,002,083
Additional convertible debentures issued				$ 210,000
Related Party [Member]
Payment to acquired real estate from a related party	$ 300,000		$ 480,000
Purchase price from acquisition			$ 265,000
Related Party [Member] | 5% Series A Convertible Preferred Stock [Member]
Number of shares issuance (in shares)	300		215
Number of converted shares	100
Related Party [Member] | Building Improvements [Member]
Payment to acquired real estate from a related party	$ 265,000		$ 405,000
Related Party [Member] | Land [Member]
Payment to acquired real estate from a related party	$ 35,000		$ 75,000

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Mar. 23, 2016	Feb. 09, 2016	Feb. 01, 2016	Dec. 31, 2015	Dec. 30, 2015	Nov. 12, 2015	Oct. 15, 2015	Nov. 30, 2014	Jun. 30, 2016	Oct. 13, 2015	Jun. 30, 2015
Common Stock, authorized									450,000,000	450,000,000	450,000,000
Preferred stock, authorized									5,000	5,000	5,000
Preferred stock, par value (in dollars per share)									$ 1,000		$ 1,000
Line of credit outstanding									$ 1,000,495
Fair market value of shares									300,000
Number of shares received, value									$ (76,102)
Warrant [Member]
Number of outstanding warrants									7,452,959
Warrant expiration									Nov. 7, 2016
PrivateEquity Sale [Member]
Number of shares on private equity sale								14,905,918
Proceeds on sale of private equity								$ 49,900
PrivateEquity Sale [Member] | Warrant [Member]
Number of shares issued								77,452,959
Exercise price of warrants (in dollars per share)								$ 0.005
5% Series A Convertible Preferred Stock [Member]
Preferred stock, authorized						2,750			2,750		2,750
Preferred stock, value, issued									$ 1,240,000
Preferred stock, par value (in dollars per share)						$ 1,000			$ 1,000		$ 1,000
Description of voting rights						The holders of the Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, payable quarterly in cash, or at the Company’s option, such dividends shall be accreted to, and increase, the stated value of the issued Series A Preferred Stock (which we refer to as “PIK”). Holders of the Series A Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series A Preferred Stock may be converted.
Preferred stock, paid-in-kind, per share						$ 0.015
5% Series B Convertible Preferred Stock [Member]
Preferred stock, authorized									1,250		1,250
Preferred stock, value, issued									$ 1,250,000
Preferred stock, par value (in dollars per share)									$ 1,000		$ 1,000
Description of voting rights									Holders of the Series B Preferred Stock are entitled to votes on all matters submitted to stockholders at a rate of ten votes for each share of common stock into which the Series B Preferred Stock may be converted.
Description of conversion basic									After nine months from issuance, each share of Series B Preferred Stock is convertible, at the option of the holder, into the number of shares of common stock equal to the quotient of the stated value, as adjusted for PIK dividends, by $0.01, as adjusted for stock splits and dividends.
Number of shares issued									250
Fair market value of shares									$ 250,000
Related Party [Member]
Cash and marketable securities					$ 1,862,458
Line of credit outstanding					$ 980,000
Related Party [Member] | Loan Agreement With Bank [Member]
Debt conversion amount				$ 100,000
Related Party [Member] | 5% Series A Convertible Preferred Stock [Member]
Number of shares issued upon acquisition				300		215
Number of shares issued upon conversion				100
Related Party [Member] | 5% Series B Convertible Preferred Stock [Member]
Number of shares issued					1,000
Officer [Member] | 5% Series B Convertible Preferred Stock [Member]
Number of shares received			250
Number of shares received, value			$ 250,000
G. Darcy Klug (Beechwood Properties, LLC) [Member] | 5% Series A Convertible Preferred Stock [Member] | Tower Hotel Fund 2013 LLC [Member]
Number of shares issued upon acquisition				625
Securities Purchase Agreement [Member]
Number of shares issued	10,000,000						5,000,000
Fair market value of shares	$ 260,000						$ 50,000
Settlement Agreement [Member]
Transaction cost of equity		$ 33,602
Settlement Agreement [Member] | Former Officer and Director [Member]
Number of shares issued		18,021,535
Litigation settlement, amount		$ 42,500

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) - USD ($)	5 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jan. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Operating Loss			$ (147,739)
Net Loss from Discontinued Operations			$ (147,739)

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Net operating losses carried forward	$ 2,400,000	$ 1,100,000
Net operating loss carryforward	$ 800,000	$ 400,000
US federal income tax rate (in percent)	100.00%

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) - USD ($)	5 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jan. 31, 2015
Segment Reporting Information [Line Items]
Operating revenues	$ 385	$ 29,450	$ 225
Operating income (loss)	(105,615)	(1,414,222)	(197,149)
Interest expense		35,189	$ 519
Depreciation and amortization		87,143
Identifiable assets	$ 245,617	3,638,816
LAND & HOSPITALITY [Member]
Segment Reporting Information [Line Items]
Operating revenues		24,700
Operating income (loss)		(5,364)
Interest expense		9,843
Depreciation and amortization		18,479
Identifiable assets		1,396,780
MEDICAL DEVICE & PHARMA [Member]
Segment Reporting Information [Line Items]
Operating revenues
Operating income (loss)		(521,025)
Interest expense
Depreciation and amortization		68,664
Identifiable assets		917,902
OTHER SERVICES [Member]
Segment Reporting Information [Line Items]
Operating revenues		4,750
Operating income (loss)		(22,881)
Interest expense
Depreciation and amortization
Identifiable assets		5,529
CORPORATE [Member]
Segment Reporting Information [Line Items]
Operating revenues
Operating income (loss)		(864,952)
Interest expense		25,346
Depreciation and amortization
Identifiable assets		$ 1,318,605

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Sep. 26, 2016	Jun. 30, 2016
5% Secured Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Additional convertible debentures issued		$ 210,000
Subsequent Event [Member] | Marlin USA Energy Partners LLC (Minority owner of Tigress Energy Partners, LLC) [Member]
Subsequent Event [Line Items]
Minority ownership percentage	25.00%
Cash investment	$ 70,000
Subsequent Event [Member] | 5% Secured Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Additional convertible debentures issued		$ 210,000